| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00428-018-2416-Z |
| P698 | PubMed publication ID | 30033510 |
| P50 | author | Hironobu Sasano | Q61126397 |
| P2093 | author name string | Satoshi Takahashi | |
| Puay Hoon Tan | |||
| Aye Aye Thike | |||
| Valerie Cui Yun Koh | |||
| P2860 | cites work | Surfing the p53 network | Q28032484 |
| Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies | Q33593016 | ||
| Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study | Q33758934 | ||
| Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. | Q34220452 | ||
| Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study | Q34493998 | ||
| Pathology of ductal carcinoma in situ of the breast: a heterogeneous entity in need of greater understanding | Q34510492 | ||
| Decision making by p53: life, death and cancer | Q35116663 | ||
| Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 | Q35130819 | ||
| Biological Markers Predictive of Invasive Recurrence in DCIS. | Q35181071 | ||
| Effects of HER2 overexpression on cell signaling networks governing proliferation and migration | Q35194023 | ||
| The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease | Q35201328 | ||
| A Comparative Analysis of Biomarker Expression and Molecular Subtypes of Pure Ductal Carcinoma In Situ and Invasive Breast Carcinoma by Image Analysis: Relationship of the Subtypes with Histologic Grade, Ki67, p53 Overexpression, and DNA Ploidy | Q35684433 | ||
| Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival | Q35749421 | ||
| Current treatment and clinical trial developments for ductal carcinoma in situ of the breast | Q37022884 | ||
| Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer | Q37198196 | ||
| HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer | Q37270033 | ||
| Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ. | Q37509632 | ||
| Age at diagnosis predicts local recurrence in women treated with breast-conserving surgery and postoperative radiation therapy for ductal carcinoma in situ: a population-based outcomes analysis | Q37577706 | ||
| In search of triple-negative DCIS: tumor-type dependent model of breast cancer progression from DCIS to the invasive cancer | Q38064799 | ||
| p53 mutations in cancer | Q38069463 | ||
| Progression from ductal carcinoma in situ to invasive breast cancer: revisited | Q38124521 | ||
| Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer | Q38429498 | ||
| Ductal carcinoma in situ associated with triple negative invasive breast cancer: evidence for a precursor-product relationship | Q39443325 | ||
| Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study | Q39605778 | ||
| Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers | Q39870616 | ||
| Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients | Q40832706 | ||
| Prognostic and predictive factors in breast cancer by immunohistochemical analysis. | Q40866567 | ||
| Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer | Q42461856 | ||
| Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma | Q42466578 | ||
| Expression of p53 protein product in triple negative breast cancers and relation with clinical and histopathological parameters. | Q42478369 | ||
| HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component. | Q42480187 | ||
| Breast cancer molecular subtypes respond differently to preoperative chemotherapy | Q42482998 | ||
| Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer | Q42491858 | ||
| The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes | Q42511189 | ||
| HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism | Q42801752 | ||
| Prognostic significance of molecular classification of breast invasive ductal carcinoma. | Q44404534 | ||
| High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. | Q44803638 | ||
| Long-term impact of young age at diagnosis on treatment outcome and patterns of failure in patients with ductal carcinoma in situ treated with breast-conserving therapy | Q44887227 | ||
| Triple-negative breast cancer: histological subtypes and immunohistochemical and clinicopathological features | Q45181661 | ||
| Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype. | Q49061414 | ||
| Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. | Q50592584 | ||
| The Relationships between HER2 Overexpression and DCIS Characteristics. | Q51016417 | ||
| Female breast cancer status according to ER, PR and HER2 expression: a population based analysis. | Q51478567 | ||
| Molecular phenotypes of DCIS predict overall and invasive recurrence. | Q53617890 | ||
| Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update | Q57130157 | ||
| p53 Overexpression is a Predictor of Local Recurrence After Treatment for Both in situ and Invasive Ductal Carcinoma of the Breast | Q57892837 | ||
| Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or an obligate precursor of invasive disease? | Q64019030 | ||
| p53 protein expression in ductal carcinoma in situ (DCIS) of the breast | Q73144803 | ||
| Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes | Q73341667 | ||
| Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways | Q77976506 | ||
| The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up | Q81731306 | ||
| P433 | issue | 3 | |
| P921 | main subject | biomarker | Q864574 |
| ductal carcinoma | Q5311598 | ||
| P304 | page(s) | 275-283 | |
| P577 | publication date | 2018-07-23 | |
| P1433 | published in | Virchows Archiv | Q19059548 |
| P1476 | title | Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile | |
| P478 | volume | 473 |
| Q92423196 | Towards the early detection of ductal carcinoma (a common type of breast cancer) using biomarkers linked to the PPAR(γ) signaling pathway | cites work | P2860 |
Search more.